Clinical Trial Update: Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10) [Phase 2]

View source ↗

Summary

Phase 2 trial exploring cryoablation with tislelizumab and lenvatinib as first-line therapy for advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)
• cryotherapy/cryoablation

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN